Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30685431 | 1.00 | MEN1 (0.43) | MEN1KMT2AABHD6HDAC8PTPN1 | |
| SCHEMBL24602628 | 0.90 | ABHD6 (0.40) | MEN1KMT2AABHD6HDAC8PTPN1 | |
| SCHEMBL26914843 | 0.85 | MEN1 (0.47) | MEN1KMT2AABHD6HDAC8PTPN1 | |
| SCHEMBL31621613 | 0.84 | MEN1 (0.41) | MEN1KMT2AABHD6HDAC8PTPN1 | |
| SCHEMBL31621568 | 0.84 | MEN1 (0.41) | MEN1KMT2AABHD6HDAC8PTPN1 | |
| SCHEMBL24602711 | 0.84 | MEN1 (0.41) | MEN1KMT2AABHD6HDAC8PTPN1 | |
| SCHEMBL24602685 | 0.83 | ABHD6 (0.42) | MEN1KMT2AABHD6HDAC8PTPN1 | |
| SCHEMBL26914866 | 0.82 | ABHD6 (0.36) | MEN1KMT2AABHD6HDAC8PTPN1 | |
| SCHEMBL31621607 | 0.82 | ABHD6 (0.44) | MEN1KMT2AABHD6HDAC8PTPN1 | |
| SCHEMBL31621630 | 0.82 | ABHD6 (0.44) | MEN1KMT2AABHD6HDAC8PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115703776-B | Plasmin inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-20240300986-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2024-09-12 | — | — | US | disclosed |
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4289850-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4289850-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4273135-A1 | PLASMIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273135-A1 | PLASMIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-116848122-A | Plasmin inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116710440-A | Plasmin inhibitor, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2022166845-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 赛诺哈勃药业（成都）有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2022143911-A1 | PLASMIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 赛诺哈勃药业（成都）有限公司 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022143911-A1 | PLASMIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 赛诺哈勃药业（成都）有限公司 | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124443-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | F2, PLG, PLAT | MEN1 726/4885KMT2A 2898/4885ABHD6 2535/4885 |
| US-20240300986-A1 | PLASMIN INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | F2, PLG, PLAT | MEN1 993/4885KMT2A 3791/4885ABHD6 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.